Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland | Zendy

Arjun Bhadhuri | Zendy; Ralph P. Insinga | Zendy; Patrik Guggisberg | Zendy; Cdric M. Panje | Zendy; Matthias Schwenkglenks | Zendy

Open Access

Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland

Author(s) -

Arjun Bhadhuri,

Ralph P. Insinga,

Patrik Guggisberg,

Cdric M. Panje,

Matthias Schwenkglenks

Publication year - 2019

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2019.20170

Subject(s) - pembrolizumab , medicine , lung cancer , oncology , cost effectiveness , chemotherapy , adverse effect , cost effectiveness analysis , quality of life (healthcare) , cancer , immunotherapy , risk analysis (engineering) , nursing

Pembrolizumab is likely to be cost effective for treating Swiss patients with previously untreated metastatic NSCLC expressing PD-L1 TPS ≥50%. (This economic evaluation was based on the KEYNOTE-024 trial. The trial identifier is NCT02142738.).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research